Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 11:30 PM
Ignite Modification Date: 2025-12-25 @ 9:17 PM
NCT ID: NCT04697056
Description: Safety analysis set included all randomized participants who received at least 1 dose of imsidolimab or placebo.
Frequency Threshold: 0
Time Frame: From first dose up to study termination (maximum up to 9.4 weeks)
Study: NCT04697056
Study Brief: A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Imsidolimab Participants received a starting dose of 400 mg of imsidolimab on Day 1 followed by 200 mg imsidolimab every four 4 (Days 29, 57 and 85) by subcutaneous injection. 0 None 0 4 1 4 View
Placebo Participants received imsidolimab matching placebo on Day 1 and thereafter every four 4 (Days 29, 57 and 85) by subcutaneous injection. 0 None 0 1 1 1 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Fatigue NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (24.1) View
Peripheral swelling NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (24.1) View
Herpes simplex reactivation NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (24.1) View
Procedural pain NON_SYSTEMATIC_ASSESSMENT Injury, poisoning and procedural complications MedDRA (24.1) View
Inguinal mass NON_SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (24.1) View
Headache NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (24.1) View
Night sweats NON_SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (24.1) View
Skin lesion NON_SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (24.1) View